{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"What makes life science angel investment work?","slug":"what-makes-life-science-angel-investment-work","published_at":"2026-04-30T05:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/what-makes-life-science-angel-investment-work","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/65c69fa239e2f1d7e387306e65496a3bc92ceef0c99b4a19b9723dc52aba6c41/eyJlcGlzb2RlSWQiOiI5NmY2Mjc0YS0wNmEyLTRmYzctYWVhYi02ZWYzM2IyNGIwMmQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNjlmMGY1NDA4NWVlOTg3NTBlZDVlODY4L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi00LTI4X18xOS01OC0yNC5tcDMifQ==.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/65c69fa239e2f1d7e387306e65496a3bc92ceef0c99b4a19b9723dc52aba6c41/eyJlcGlzb2RlSWQiOiI5NmY2Mjc0YS0wNmEyLTRmYzctYWVhYi02ZWYzM2IyNGIwMmQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNjlmMGY1NDA4NWVlOTg3NTBlZDVlODY4L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi00LTI4X18xOS01OC0yNC5tcDMifQ==.mp3","summary":"In this episode of Denatured, you'll be hearing from Yaniv Sneor, founder of the Mid Atlantic Bio Angels and Alex Pederson, an investor at Mid Atlantic Bio Angels and partner at Alloy Bio Consulting. We discuss why a life sciences-only angel group matters, how they evaluate opportunities, and the importance of strong teams, capital efficiency and a realistic path to exit. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Yaniv Sneor , Founder, Mid Atlantic Bio Angels Alex Pederson , Investor, Mid Atlantic Bio Angels & Partner, Alloy Bio Consulting Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, you'll be hearing from Yaniv Sneor, founder of the Mid Atlantic Bio Angels and Alex Pederson, an investor at Mid Atlantic Bi…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1300,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/what-makes-life-science-angel-investment-work/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/what-makes-life-science-angel-investment-work.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}